Dazhao Mi

Shanghai Key Laboratory Of Regulatory Biology
Shanghai, 200241, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Discovery of novel cereblon-recruiting PRMT5 degraders with in vivo efficacy against triple-negative breast cancer.

Discovery of novel cereblon-recruiting PRMT5 degraders with in vivo efficacy against triple-negative breast cancer.

Journal: European journal of medicinal chemistry

Published: May 25, 2026

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer.

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 21, 2024

A long march for targeted protein degradation in the new era: expanding E3 ligases.

A long march for targeted protein degradation in the new era: expanding E3 ligases.

Journal: Future medicinal chemistry

Published: October 07, 2024

Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo.

Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo.

Journal: European journal of medicinal chemistry

Published: June 14, 2024

Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer.

Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer.

Journal: Journal of medicinal chemistry

Published: December 06, 2023

Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer.

Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer.

Journal: Journal of medicinal chemistry

Published: May 22, 2023

Corrigendum to "Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway" [Canc. Lett. (2023) 216142].

Corrigendum to "Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway" [Canc. Lett. (2023) 216142].

Journal: Cancer letters

Published: May 08, 2023

Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design.

Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design.

Journal: European journal of medicinal chemistry

Published: March 29, 2023

Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway.

Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway.

Journal: Cancer letters

Published: December 19, 2022

B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.

B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.

Journal: Journal of medicinal chemistry

Published: November 28, 2022

An instructive attempt on developing aptamer-constructed PROTAC for breast cancer treatment.

An instructive attempt on developing aptamer-constructed PROTAC for breast cancer treatment.

Journal: Molecular therapy. Nucleic acids

Published: November 16, 2022

A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer.

A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer.

Journal: Cancer letters

Published: November 10, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026